Liquidia Corporation (LQDA) |
|
6.91 0.17 (2.52%)
|
03-31 16:00 |
|
Open: |
6.76 |
Pre. Close: |
6.74 |
|
High:
|
7 |
Low:
|
6.76 |
|
Volume:
|
766,298 |
Market Cap:
|
447(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:15 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 9.09 One year: 10.62 |
| Support: |
Support1: 6.7 Support2: 6.03 |
| Resistance: |
Resistance1: 7.78 Resistance2: 9.09 |
| Pivot: |
6.87 |
| Moving Average: |
MA(5): 6.86 MA(20): 6.86 
MA(100): 6.31 MA(250): 5.7 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 51.4 %D(3): 51.6 |
| RSI: |
RSI(14): 49.5 |
| 52-week: |
High: 8.78 Low: 3.25 |
| Average Vol(K): |
3-Month: 504 (K) 10-Days: 410 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LQDA ] has closed below upper band by 46.7%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.01 - 7.04 |
7.04 - 7.07 |
|
Low:
|
6.68 - 6.72 |
6.72 - 6.75 |
|
Close:
|
6.85 - 6.91 |
6.91 - 6.96 |
|
Company Description |
|
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. |
Headline News |
Sat, 25 Mar 2023
Industry Analysts Just Made A Captivating Upgrade To Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts - Yahoo Eurosport UK
Mon, 20 Mar 2023
Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Call Transcript - Yahoo Finance
Thu, 16 Mar 2023
North American Morning Briefing : Some Calm -2- - Marketscreener.com
Mon, 13 Mar 2023
Insiders of Liquidia Corporation (NASDAQ:LQDA) are probably glad they bought last year as their US$2.6m investment now stands at US$3.2m - Simply Wall St
Fri, 10 Mar 2023
SVB shutdown forces Raleigh-Durham startups, public companies to ... - The Business Journals
Thu, 09 Mar 2023
Liquidia Corporation to Report Full Year 2022 Financial Results on ... - Kentucky Today
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
65 (M) |
| Shares Float |
46 (M) |
|
% Held by Insiders
|
12.1 (%) |
|
% Held by Institutions
|
52.7 (%) |
|
Shares Short
|
2,660 (K) |
|
Shares Short P.Month
|
3,040 (K) |
Stock Financials |
|
EPS
|
-1.76 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.63 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-316.5 |
|
Return on Assets (ttm)
|
-23.5 |
|
Return on Equity (ttm)
|
-54.9 |
|
Qtrly Rev. Growth
|
-0.5 |
|
Gross Profit (p.s.)
|
0.15 |
|
Sales Per Share
|
0.21 |
|
EBITDA (p.s.)
|
-0.66 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-32 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-3.93 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
4.21 |
|
Price to Sales
|
32.32 |
|
Price to Cash Flow
|
-14.14 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
